ReviewJournal of rheumatic diseases2023
Updates on ankylosing spondylitis: pathogenesis and therapeutic agents.
Review in Journal of rheumatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Association between TNF-α polymorphisms and responsiveness to TNF-α blockers in ankylosing spondylitis and psoriatic arthritis: a meta-analysis.Scientific reports · 2026Pooled it
- Ankylosing spondylitis and the gut microbiome: future research hotspots and trends.Frontiers in immunology · 2026Pooled it
- Transforming growth factor-β1 promotes initiation of entheseal pathological bone formation via osteonectin induction in ankylosing spondylitis.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Improving exercise adherence in ankylosing spondylitis through individualized education and follow-up: a pilot randomized trial.Irish journal of medical science · 2026Article
- Tumor necrosis factor inhibitor prescribing and persistence by specialty in radiographic axial spondyloarthritis: a Korean claims study.The Korean journal of internal medicine · 2026Article
- Catheter-assisted evacuation through limited laminectomy for traumatic long-segment spinal epidural hematoma in ankylosing spondylitis: a technical note and two case reports.BMC musculoskeletal disorders · 2026Article
- Association between systemic inflammation-immune index and comorbidities in patients with ankylosing spondylitis: a cross-sectional study.Clinical rheumatology · 2026Article
- Progression to Radiographic Axial Spondyloarthritis: A Narrative Review on Timeline and Novel Prediction Factors.International journal of molecular sciences · 2026Review
- Combined detection of HLA-B27, ESR, and CRP as biochemical and immunogenetic markers in the auxiliary diagnosis of ankylosing spondylitis.Journal of medical biochemistry · 2026Article
- Single-Cell Genetic Mapping of Gasdermin Expression Across Immune-Mediated Inflammatory Diseases.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Comprehensive overview of alternative medicine in the treatment of ankylosing spondylitis: Symptoms, pathogenesis, diagnosis and treatments (Review).Biomedical reports · 2026Review
- Risk-stratified management of ankylosing spondylitis-related spinal fractures-a meta-synthesis of contemporary surgical and nonsurgical strategies: a narrative review.Journal of spine surgery (Hong Kong) · 2025Review
- Kynurenic Acid Analog Attenuates the Production of Tumor Necrosis Factor-α, Calgranulins (S100A 8/9 and S100A 12), and the Secretion of HNP1-3, and Stimulates the Production of Tumor Necrosis Factor-Stimulated Gene-6 (TSG-6) but Does Not Alter IL-17 Levels in Whole-Blood Cultures of Patients with Spondyloarthritis.International journal of molecular sciences · 2025Article
- Review
- Age-Specific Risk Factors for Cancer in a Long-Term Korean Cohort of Patients with Ankylosing Spondylitis Treated with TNF Inhibitors.Journal of clinical medicine · 2025Article
- Association between immunoglobulin G N-glycosylation, inflammatory factors, and ankylosing spondylitis: A case-control study.Clinical rheumatology · 2025Article
- Gut Microbiota Mediator Level and Its Relation to Disease Activity in Ankylosing Spondylitis.Archives of rheumatology · 2025Article
- Retention rate of TNF inhibitors versus IL-17 inhibitors in ankylosing spondylitis patients with prior biologics experience.Arthritis research & therapy · 2025Article
- A Pilot Study on the Anti-Inflammatory Effects of Tacrolimus in Ankylosing Spondylitis: Evidence from Human Samples and a Murine Model.Archives of rheumatology · 2025Article
- The Genetic Background of Ankylosing Spondylitis Reveals a Distinct Overlap with Autoimmune Diseases: A Systematic Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ankylosing spondylitis (AS) is an autoinflammatory disease that manifests with the unique feature of enthesitis. Gut microbiota, HLA-B*27, and biomechanical stress mutually influence and interact resulting in setting off a flame of inflammation. In the HLA-B*27 positive group, dysbiosis in the gut environment disrupts the barrier to exogenous bacteria or viruses. Additionally, biomechanical stress induces inflammation through enthesial resident or gut-origin immune cells. On this basis, innate and adaptive immunity can propagate inflammation and lead to chronic disease. Finally, bone homeostasis is regulated by cytokines, by which the inflamed region is substituted into new bone. Agents that block cytokines are constantly being developed to provide diverse therapeutic options for preventing the progression of inflammation. In addition, some antibodies have been shown to distinguish disease selectively, which support the involvement of autoimmune immunity in AS. In this review, we critically analyze the complexity and uniqueness of the pathogenesis with updates on the findings of immunity and provide new information about biologics and biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.